Richard Furie

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Richard Furie, Michelle Petri, Omid Zamani et al. · Arthritis & Rheumatism · 2011 · 1.7K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

Brad H. Rovin, Richard Furie, Kevin Latinis et al. · Arthritis & Rheumatism · 2012 · 1.4K citations

Medicine, Immunology, Pharmacotherapy +16

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Eric F. Morand, Richard Furie, Yoshiya Tanaka et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +9

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

Richard Furie, Brad H. Rovin, Frédéric Houssiau et al. · New England Journal of Medicine · 2020 · 973 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12